MOIA, RICCARDO
 Distribuzione geografica
Continente #
EU - Europa 1.293
NA - Nord America 1.120
AS - Asia 981
SA - Sud America 166
AF - Africa 69
OC - Oceania 2
Totale 3.631
Nazione #
US - Stati Uniti d'America 1.052
SG - Singapore 391
IT - Italia 373
IE - Irlanda 274
HK - Hong Kong 200
DE - Germania 173
CN - Cina 146
BR - Brasile 141
SE - Svezia 129
RU - Federazione Russa 105
VN - Vietnam 72
GB - Regno Unito 57
IN - India 57
CA - Canada 42
BJ - Benin 40
FR - Francia 39
FI - Finlandia 37
KR - Corea 36
UA - Ucraina 30
MX - Messico 24
ID - Indonesia 16
PL - Polonia 15
TR - Turchia 14
AT - Austria 13
BD - Bangladesh 13
ZA - Sudafrica 13
JP - Giappone 12
LT - Lituania 12
ES - Italia 9
AR - Argentina 8
NL - Olanda 7
CZ - Repubblica Ceca 6
ET - Etiopia 6
BE - Belgio 5
EC - Ecuador 5
IR - Iran 5
PE - Perù 4
AL - Albania 3
CO - Colombia 3
HR - Croazia 3
IQ - Iraq 3
KE - Kenya 3
SA - Arabia Saudita 3
VE - Venezuela 3
AU - Australia 2
CL - Cile 2
EG - Egitto 2
IL - Israele 2
KG - Kirghizistan 2
MA - Marocco 2
SY - Repubblica araba siriana 2
AE - Emirati Arabi Uniti 1
AO - Angola 1
AZ - Azerbaigian 1
BY - Bielorussia 1
DK - Danimarca 1
DZ - Algeria 1
GE - Georgia 1
HN - Honduras 1
JM - Giamaica 1
LB - Libano 1
MK - Macedonia 1
NG - Nigeria 1
OM - Oman 1
PS - Palestinian Territory 1
TW - Taiwan 1
Totale 3.631
Città #
Dublin 272
Hong Kong 200
Singapore 152
Ashburn 112
Beijing 98
Los Angeles 67
Chandler 61
Novara 59
Jacksonville 57
Boardman 47
Munich 45
Cotonou 40
Seoul 34
Moscow 32
Lawrence 31
Piemonte 31
Princeton 31
Buffalo 30
Helsinki 30
New York 29
Bremen 23
Milan 21
Frankfurt am Main 20
Ho Chi Minh City 20
Turin 19
Vercelli 19
Dallas 18
Grafing 18
São Paulo 18
Wilmington 16
Mexico City 14
Nuremberg 13
Podenzano 13
Poplar 13
Santa Clara 13
Denver 12
Houston 12
London 12
Montreal 12
San Mateo 12
Toronto 12
Warsaw 12
Brooklyn 11
Chennai 11
Hanoi 11
Atlanta 10
Johannesburg 10
Tokyo 10
Ankara 9
Belo Horizonte 9
Boston 9
Falkenstein 9
Orem 9
Phoenix 9
Cassano Magnago 8
Redondo Beach 8
Roseto degli Abruzzi 8
Augusta 7
Ottawa 7
Addis Ababa 6
Ann Arbor 6
Bexley 6
Brno 6
Genoa 6
Menlo Park 6
Mumbai 6
Roubaix 6
Stockholm 6
Strasbourg 6
Turku 6
West Jordan 6
Berlin 5
Brussels 5
Gunzenhausen 5
Manchester 5
Rimini 5
Rio de Janeiro 5
Seattle 5
Brasília 4
Chicago 4
Haiphong 4
Poços de Caldas 4
Querétaro 4
Rome 4
Somaglia 4
Tianjin 4
Vienna 4
Andover 3
Bergamo 3
Bắc Ninh 3
Charlotte 3
City of London 3
Cologno Monzese 3
Curitiba 3
Dhaka 3
Elmas 3
Jakarta 3
Leawood 3
Monza 3
Naples 3
Totale 2.137
Nome #
International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia 113
Active AKT signaling triggers CLL towards Richter's transformation via over-activation of Notch1 107
Targeting p53 in chronic lymphocytic leukemia 92
A leukemia-protective germline variant mediates chromatin module formation via transcription factor nucleation 90
Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome 87
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 87
An update on: molecular genetics of high-risk chronic lymphocytic leukemia 86
Precision medicine management of chronic lymphocytic leukemia 86
Anti-rasburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity 85
Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma 84
Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients 82
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study 81
Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement 79
Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcome 79
Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations 77
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression 75
Stiffer Spleen Predicts Higher Bone Marrow Fibrosis and Higher JAK2 Allele Burden in Patients With Myeloproliferative Neoplasms 75
High reproducibility of spleen stiffness measurement by vibration-controlled transient elastography with a spleen-dedicated module 73
Druggable Molecular Pathways in Chronic Lymphocytic Leukemia 72
Molecular clustering on ctDNA improves the prognostic stratification of DLBCL patients compared to ctDNA levels 70
The Biology of Chronic Lymphocytic Leukemia: Diagnostic and Prognostic Implications 69
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 68
An acquired factor V inhibitor induced uncontrolled bleeding in a postsurgery patient 68
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 68
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 67
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 67
null 62
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial 61
Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib 60
Cerebrospinal fluid xanthochromia after pegasparaginase hepatotoxicity in B-cell acute lymphoblastic leukemia 59
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 59
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 59
Liquid biopsy in hematological malignancies: current and future applications 57
Reply to Aron P. Kater et al 56
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 55
Prognostic value of clonal evolution identified by sequential FISH in untreated chronic lymphocytic leukaemia 52
High Mitophagy and Low Glycolysis Predict Better Clinical Outcomes in Acute Myeloid Leukemias 52
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 52
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY 51
A Rare Case of Life-Threatening Jaundice Caused by Epstein-Barr Virus Infection and Secondary Cold Agglutinin Syndrome Successfully Treated with Rituximab 51
XPO1 mutations identify early‐stage CLL characterized by shorter time to first treatment and enhanced BCR signalling 50
Impairment of the T cell memory response in chronic lymphocytic leukemia patients after SARS-CoV-2 vaccination 46
Prognostication in chronic lymphocytic leukemia 45
High BECN1 Expression Negatively Correlates with BCL2 Expression and Predicts Better Prognosis in Diffuse Large B-Cell Lymphoma: Role of Autophagy 45
Detection of early seeding of Richter transformation in chronic lymphocytic leukemia 45
Inducible T-cell co-stimulator (ICOS) and ICOS ligand are novel players in the multiple-myeloma microenvironment 44
HL-370 Fragmentóme Profiling Reveals Distinct Molecular Subgroups of Classic Hodgkin Lymphoma 41
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY 40
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia 39
Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation 39
Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia 38
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY 38
Updated revision of the British Society of Haematology guidelines for chronic lymphocytic leukaemia 38
CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia 36
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL 35
Prevalence and clinical impact of clonal hematopoiesis of indeterminate potential (CHIP) in chronic lymphocytic leukemia and richter transformation 33
CD49d expression is included in a revised 4‐factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real‐world experience 33
The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy 29
The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands 28
Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphoma 27
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study 23
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 22
Integration of [18F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma 21
The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial 10
Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside 9
Totale 3.727
Categoria #
all - tutte 22.880
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.880


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202174 0 0 0 0 0 8 13 1 19 17 16 0
2021/2022228 2 4 10 9 19 3 23 3 5 23 60 67
2022/2023603 41 30 48 9 36 43 30 30 263 6 50 17
2023/2024344 27 28 31 11 41 11 46 4 1 17 36 91
2024/2025958 16 12 68 13 36 48 87 213 182 78 36 169
2025/20261.391 171 123 212 425 415 45 0 0 0 0 0 0
Totale 3.727